España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ehave
EHVVF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.00350
0.00050
16.67%
At close: -
$0.000001
-0.00350
-99.97%
After Hours: Aug 8, 4:50 PM EDT
Get Report
Comment
Ehave (EHVVF) Forecast
News
Earnings
Ehave (EHVVF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Ehave (OTC:EHVVF) Stock
Ehave Stock (OTC: EHVVF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 03, 2023
Combatting The 'Bad Trip': New Research Project Seeks Solutions That Go Beyond Psychedelics
Jelena Martinovic
Friday, December 16, 2022
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
Lara Goldstein
Wednesday, June 08, 2022
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
Natan Ponieman
Wednesday, June 01, 2022
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Lara Goldstein
Monday, May 23, 2022
Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
Vuk Zdinjak
Tuesday, February 22, 2022
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
Natan Ponieman
Tuesday, February 15, 2022
KetaDASH Announces Mobile Ketamine Treatments in San Francisco and Sacramento Area
Nicolas Jose Rodriguez
Monday, October 18, 2021
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
Wednesday, October 13, 2021
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman
Sunday, September 26, 2021
Cannabis Movers & Shakers: Greenlight Distribution, Petalfast, Tinley Beverage, Shryne Group, Ehave, NY Cannabis Control Board
Jelena Martinovic
Monday, December 28, 2020
2020 Was The Year of Psychedelics — Here's Why
Natan Ponieman
Saturday, December 19, 2020
Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace
Natan Ponieman
Tuesday, June 30, 2020
Digital Therapeutics Field Is Fast On The Rise, Ehave Is Advancing Research In Psychedelics And ADHD Therapy
Jaycee Tenn
Saturday, June 06, 2020
'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions
Natan Ponieman
Saturday, May 23, 2020
'Psyched': Mota Buys German Psilocybin Producer, Champignon Announces New CEO, $10M In Funding
Natan Ponieman
